#USA #LabConnect #Johnson City #AI Solution #OmniScience

Transforming Clinical Trials with Real-Time Data Access

In a groundbreaking development in the realm of clinical research, LabConnect, a prominent provider of central laboratory services, has announced a strategic partnership with OmniScience, the company behind Vivo, the first agentic AI dashboard for clinical trials. This collaboration marks a significant step toward providing sponsors with intelligent, real-time insights derived from clinical trial lab data.

Addressing Challenges in Clinical Data Management

Clinical trial data is frequently characterized by its fragmentation and complexity, leading to delays in decision-making and increased risks. By integrating LabConnect's expertise in laboratory management with OmniScience's Vivo platform, trial sponsors can now unify disparate laboratory data sets, automate oversight processes, and identify risk signals swiftly. This advancement aims to shorten trial timelines and enhance study outcomes.

Overview of Vivo

Vivo is an AI-native intelligence platform designed specifically for clinical trials, transforming how teams engage with data throughout the clinical development cycle. With its ability to integrate disparate sources and provide real-time insights, Vivo serves as a command center that enables clinical, operational, safety, and data science teams to act quickly and confidently. Vivo-Lab, a dedicated implementation of Vivo, extends this intelligence to laboratory data by streamlining laboratory workflows.

The Vivo-Lab feature highlights critical trends, anomalies, and site-level discrepancies as they arise, facilitating a shift from reactive to proactive monitoring. This proactive approach is vital for managing one of the most complex and variable data flows in clinical research.

Real-Time Actions from Laboratory Data

Angela Holmes, CEO and co-founder of OmniScience, emphasized the company's commitment to helping trial teams see and act faster. "The partnership with LabConnect extends this vision by turning laboratory data into actionable insights in real time," she noted. Wes Wheeler, CEO of LabConnect, added that integrating OmniScience's transformative AI capabilities allows laboratory results to evolve from static reports into dynamic and actionable information. Together, they bring the speed, agility, and accuracy necessary for clinical teams to make informed decisions, enhance trial efficiency, and expedite patient access to therapies.

This partnership is a testament to both organizations' dedication to innovation in clinical development. It combines LabConnect's technology-driven laboratory operations with OmniScience's AI-native approach to trial intelligence, promising a new era for clinical research.

About LabConnect

LabConnect, LLC stands at the forefront of central laboratory service provision, functional service provision (FSP), scientific consulting, and data integration and transformation services for analytically and logistically complex studies. These include areas such as immuno-oncology, cell and gene therapies, as well as rare and orphan diseases. Combining cutting-edge technology with state-of-the-art laboratories and accessible pathways to major and emerging markets, LabConnect is uniquely positioned to meet all central laboratory service needs for drug development organizations.

For more information, visit LabConnect's website or follow the company on LinkedIn.

About OmniScience

OmniScience is a leading AI company transforming clinical development with Vivo, the first agentic AI dashboard created for clinical trials. Developed by a team of Ph.D. data scientists, Vivo unifies fragmented trial data, applies intelligent automation, and delivers explainable real-time insights, enabling sponsors to reduce costs, accelerate timelines, and improve trial success rates. Awarded and recognized by programs such as Johnson & Johnson's JLABS, NVIDIA Inception, and Google Cloud for AI, OmniScience ushers in a new era of intelligent clinical trials to speed up patient access to life-changing treatments.